Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Summary

This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.

Timeline

Start

2004-12

Primary completion

2010-10

Completion

2011-12

Drugs

Indications